États-Unis · Plateformes & données · Morningstar

Novartis Raises Guidance After Trial Setbacks Hit Profit

Publié par Morningstar · États-Unis il y a 12 h

Novartis raised its full-year earnings guidance, citing solid sales growth and productivity gains, even as recent clinical-trial setbacks hit the Swiss drugmaker's bottom line in…

Lire l'article complet sur Morningstar Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.morningstar.com)

Novartis Raises Guidance After Trial Setbacks Hit Profit

À lire aussi

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

Here's How Much a $10,000 Investment in Realty Income Will Get You in Monthly Dividends

My wife cried when I found out she had only $80,000 in her 401(k). I have $2.2 million. Am I wrong to be shocked?

Inderes Q3 2026 slides: revenue climbs 11%, EBITA margin hits 22.4%

Best Stocks Under $5

Walmart copies a core Costco move that also benefits customers

Novartis Raises Guidance After Trial Setbacks Hit Profit

Partager

À lire aussi

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

Here's How Much a $10,000 Investment in Realty Income Will Get You in Monthly Dividends

My wife cried when I found out she had only $80,000 in her 401(k). I have $2.2 million. Am I wrong to be shocked?

Inderes Q3 2026 slides: revenue climbs 11%, EBITA margin hits 22.4%

Best Stocks Under $5

Walmart copies a core Costco move that also benefits customers